These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28821933)

  • 1. Effects of realgar (As
    Niu M; Shen Y; Qi J; Liu X; Sang W; Wu Q; Cao J; Chen W; Yao Y; Xu K
    Ann Hematol; 2017 Nov; 96(11):1945-1948. PubMed ID: 28821933
    [No Abstract]   [Full Text] [Related]  

  • 2. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
    Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
    Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
    Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
    Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
    Jo S; Lee YL; Kim S; Lee H; Chung H
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
    Tian Y; Liu Y; He P; Liu F; Zhou N; Cheng X; Shi L; Zhu H; Zhao J; Wang Y; Zhang M
    PLoS One; 2014; 9(1):e83184. PubMed ID: 24454695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
    Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
    Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PML-RARA mutations confer varying arsenic trioxide resistance.
    Bai DM; Zheng XF
    Protein Cell; 2017 Apr; 8(4):296-301. PubMed ID: 28028657
    [No Abstract]   [Full Text] [Related]  

  • 11. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
    Jeanne M; Lallemand-Breitenbach V; Ferhi O; Koken M; Le Bras M; Duffort S; Peres L; Berthier C; Soilihi H; Raught B; de Thé H
    Cancer Cell; 2010 Jul; 18(1):88-98. PubMed ID: 20609355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
    de Thé H; Pandolfi PP; Chen Z
    Cancer Cell; 2017 Nov; 32(5):552-560. PubMed ID: 29136503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
    Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
    Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D; Nasr R; de The H
    Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
    Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA.
    Jaffray EG; Tatham MH; Mojsa B; Liczmanska M; Rojas-Fernandez A; Yin Y; Ball G; Hay RT
    J Cell Biol; 2023 Apr; 222(4):. PubMed ID: 36880596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagic degradation of an oncoprotein.
    Bøe SO; Simonsen A
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
    Strehl S; König M; Boztug H; Cooper BW; Suzukawa K; Zhang SJ; Chen HY; Attarbaschi A; Dworzak MN
    Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
    Zhang X; Pan J
    Ann Hematol; 2017 Apr; 96(4):707-708. PubMed ID: 28154895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.